| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439580 | European Journal of Cancer | 2018 | 8 Pages |
Abstract
This crossover study of patients with advanced RCC demonstrated potent tivozanib anti-tumour activity. Safety and tolerability profiles were acceptable and consistent with the established adverse event profile of tivozanib.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ana M. Molina, Thomas E. Hutson, Dmitry Nosov, Piotr Tomczak, Oleg Lipatov, Cora N. Sternberg, Robert Motzer, Tim Eisen,